YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Dave Nadig talks through his zine at the ETF Oasis at Future Proof ETFs are like family to me. I've spent most of my career in the ETF weeds, and for what felt like pretty noble reasons: they've made investing cheaper, easier and more tran…
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv…
INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to in…
INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therap…
NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders…
NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed merge…
NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders…
NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE: BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agre…
Here is your Pro Recap of four head-turning deal dispatches you may have missed this week: IBM and Apptio merger rumors, Eli Lilly acquires Dice Therapeutics, Amazon's iRobot acquisition faces EU antitrust investigation, and Stratasys dete…
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders…
NEW YORK, June 21, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Secur…
You might say that Eli Lilly and Co. (NYSE: LLY) is rolling the dice. The big drugmaker announced on Tuesday that it plans to acquire Dice Therapeutics (NASDAQ: DICE) in an all-cash transaction valued at around $2.4 billion. Why is Lilly b…
Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. (NYSE:LLY) announced on Tuesday it is acquiring Dice Therapeutics Inc. (NASDAQ:DICE) in a deal valued…
Eli Lilly And Co (NYSE: LLY) has agreed to acquire DICE Therapeutics Inc (NASDAQ: DICE), a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral therapeutic candidates for immunology indicati…
Shares of Dice Therapeutics (NASDAQ: DICE) were up more than 37% early Tuesday morning after the healthcare company announced it was being bought out by pharmaceutical company Eli Lilly (NYSE: LLY). Dice is a clinical-stage biotech company…
Investing.com -- Stocks are falling after stronger-than-expected data on housing stoked fresh fears about interest rates. Here are the market movers for June 20. Rivian Automotive Inc (NASDAQ:RIVN) shares are up 5% after the electric vehic…
Stock index futures suggested that might be the case, with most major benchmarks indicating modest declines of around a third of a percent in premarket trading. Dice Therapeutics (NASDAQ: DICE) made a huge move higher on merger news, while…
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmac…
SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel o…
First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in…
SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel or…
SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel…
IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023First participants dosed in Phase 1 clinical trial o…
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to…
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to t…
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to t…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. DICE Therapeutics, Inc. (DICE) is a stock that can certainly grab the attention of many investors, but do its recent return…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has DICE Therapeutics, Inc. (DICE) been one of those stocks this year? By taking a look at the stock's y…
The share price of Lantheus Holdings (NASDAQ: LNTH) has nearly doubled in 2022. Much of the gain for the stock came after Lantheus reported its 2021 Q4 results in late February. Lantheus develops imaging diagnostics, targeted therapeutics,…
Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasisDemonstrated direct inhibition of a cytokine with a small molecule…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to t…
Hellman & Friedman disclosed a large stake in cybersecurity firm Splunk. Edenbrook Capital raised its stake in security-and-analytics firm Cognyte. Continue reading
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to t…
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to t…
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to t…
The stock market has been in bear market mode throughout 2022, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) has been one of the hardest-hit stock market indexes during the rout. After seeing a new closing low for the year on Monday, inves…